First line therapy in stage IV BRAF mutated colorectal cancer
Our review suggests that a CT doublet with bevacizumab is the most favorable option for OS. However, a reasonable alternative could be a triplet CT without bevacizumab.
Authors
- Michele Ghidini (ORCID: https://orcid.org/0000-0001-5435-1218)
- Ornella Garrone (ORCID: https://orcid.org/0000-0001-7359-5410)
- Maria Antista (ORCID: https://orcid.org/0000-0002-6153-1863)
- Marcella Arru
- Alessandro Russo (ORCID: https://orcid.org/0000-0003-3846-4620)
- Fausto Petrelli (ORCID: https://orcid.org/0000-0001-9639-4486)
- Roberta Invernizzi
- Chiara Cremolini (ORCID: https://orcid.org/0000-0002-0520-4841)
- Lorenzo Dottorini (ORCID: https://orcid.org/0000-0002-2273-0229)
- Gianluca Tomasello (ORCID: https://orcid.org/0009-0005-0941-8547)
- Mariangela Manzoni
- Alberto Zaniboni
Institutions
- University of Pisa (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Azienda Ospedaliera Ospedale Maggiore (IT)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Azienda Ospedaliera Treviglio (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Azienda Socio Sanitaria Territoriale di Bergamo Ovest
Publication Details
- Journal
- Heliyon
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e36497
- Citations
- 4
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.13